Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20738457 | 0.80 | SLC6A3 (0.34) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL7176893 | 0.80 | TLR7 (0.37) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL19387943 | 0.80 | SLC6A3 (0.34) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23729956 | 0.77 | SLC6A3 (0.36) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22428740 | 0.77 | SLC6A3 (0.33) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL25998129 | 0.74 | SLC6A3 (0.34) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL8881509 | 0.72 | APEX1 (0.34) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL9260468 | 0.72 | TLR7 (0.33) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB | |
| SCHEMBL20780330 | 0.71 | CCR4 (0.36) | TLR7PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12558853 | 0.71 | CCR4 (0.36) | SLC6A3TLR7PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397914-A1 | BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397914-A1 | BENZODIAZEPINE DERIVATIVES | GABRA5, GABRA3, GABRA1 | SLC6A3 128/4885TLR7 3115/4885PIK3CD 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.